Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
Details : ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation.
Brand Name : ONC201
Molecule Type : Small molecule
Upfront Cash : $39.0 million
January 08, 2021
Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH
Details : ONC206 is the second clinical-stage imipridone that is under clinical investigation for central nervous system tumors. The study will evaluate the safety and clinical activity of ONC206 in patients with CNS malignancies.
Brand Name : ONC206
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2020
Lead Product(s) : ONC212
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212
Details : European Patent Office has granted a Composition of Matter patent for ONC212. The company also announced that a pending ONC201 patent has been granted for Mexico and that it received a Certificate of Grant for a Composition of Matter patent for ONC201 in...
Brand Name : ONC212
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2020
Lead Product(s) : ONC212
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma
Details : Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics to receive a Rare Pediatric Disease Priority Review Voucher.
Brand Name : ONC201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2020
Details : The data presented at ASCO 2020 highlights the potential of ONC201 to address the substantial need for patients with H3 K27M-mutant glioma.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2020
Phase I/II Clinical Study of ONC201 Begins in Japan
Details : Clinical trial provides Japanese patients with high-grade glioma immediate access to ONC201. Data from this study will be an important part of working toward a Japanese market approval for ONC201.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2020
Additional Composition of Matter Patent in China Expands ONC201’s Global Coverage
Details : With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2020
LOOKING FOR A SUPPLIER?